Although c-Myc inhibition would be a powerful approach for the treatment of cancers, strategies to directly target c-Myc have not yet been achieved because c-Myc is easy to be degraded through the ubiquitin-proteasome pathway [25,28]. The gene discussed is MYC; the disease is cancer.